{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:59:55Z","timestamp":1794052795836,"version":"4.8.0"},"reference-count":28,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) combination therapy in BRAF V600E\u2013mutated anaplastic thyroid cancer, a rare, aggressive, and highly lethal malignancy with poor patient outcomes and no systemic therapies with clinical benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this phase II, open-label trial, patients with predefined BRAF V600E\u2013mutated malignancies received dabrafenib 150 mg twice daily and trametinib 2 mg once daily until unacceptable toxicity, disease progression, or death. The primary end point was investigator-assessed overall response rate. Secondary end points included duration of response, progression-free survival, overall survival, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixteen patients with BRAF V600E\u2013mutated anaplastic thyroid cancer were evaluable (median follow-up, 47 weeks; range, 4 to 120 weeks). All patients had received prior radiation treatment and\/or surgery, and six had received prior systemic therapy. The confirmed overall response rate was 69% (11 of 16; 95% CI, 41% to 89%), with seven ongoing responses. Median duration of response, progression-free survival, and overall survival were not reached as a result of a lack of events, with 12-month estimates of 90%, 79%, and 80%, respectively. The safety population was composed of 100 patients who were enrolled with seven rare tumor histologies. Common adverse events were fatigue (38%), pyrexia (37%), and nausea (35%). No new safety signals were detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dabrafenib plus trametinib is the first regimen demonstrated to have robust clinical activity in BRAF V600E\u2013mutated anaplastic thyroid cancer and was well tolerated. These findings represent a meaningful therapeutic advance for this orphan disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2017.73.6785","type":"journal-article","created":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T15:55:42Z","timestamp":1509033342000},"page":"7-13","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":850,"title":["Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic\n                    <i>BRAF<\/i>\n                    V600\u2013Mutant Anaplastic Thyroid Cancer"],"prefix":"10.1200","volume":"36","author":[{"given":"Vivek","family":"Subbiah","sequence":"first","affiliation":[{"name":"Vivek Subbiah and Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert J. Kreitman, National Institutes of Health, Bethesda, MD; Zev A. Wainberg, University of California Los Angeles, Los Angeles, CA; Jae Yong Cho, Yonsei University College of Medicine Gangnam Severance Hospital; Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht Institute for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Kreitman","sequence":"additional","affiliation":[{"name":"Vivek Subbiah and Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert J. Kreitman, National Institutes of Health, Bethesda, MD; Zev A. Wainberg, University of California Los Angeles, Los Angeles, CA; Jae Yong Cho, Yonsei University College of Medicine Gangnam Severance Hospital; Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht Institute for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zev A.","family":"Wainberg","sequence":"additional","affiliation":[{"name":"Vivek Subbiah and Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert J. Kreitman, National Institutes of Health, Bethesda, MD; Zev A. Wainberg, University of California Los Angeles, Los Angeles, CA; Jae Yong Cho, Yonsei University College of Medicine Gangnam Severance Hospital; Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht Institute for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Yong","family":"Cho","sequence":"additional","affiliation":[{"name":"Vivek Subbiah and Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert J. Kreitman, National Institutes of Health, Bethesda, MD; Zev A. Wainberg, University of California Los Angeles, Los Angeles, CA; Jae Yong Cho, Yonsei University College of Medicine Gangnam Severance Hospital; Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht Institute for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.M.","family":"Schellens","sequence":"additional","affiliation":[{"name":"Vivek Subbiah and Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert J. Kreitman, National Institutes of Health, Bethesda, MD; Zev A. Wainberg, University of California Los Angeles, Los Angeles, CA; Jae Yong Cho, Yonsei University College of Medicine Gangnam Severance Hospital; Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht Institute for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Charles","family":"Soria","sequence":"additional","affiliation":[{"name":"Vivek Subbiah and Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert J. Kreitman, National Institutes of Health, Bethesda, MD; Zev A. Wainberg, University of California Los Angeles, Los Angeles, CA; Jae Yong Cho, Yonsei University College of Medicine Gangnam Severance Hospital; Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht Institute for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y.","family":"Wen","sequence":"additional","affiliation":[{"name":"Vivek Subbiah and Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert J. Kreitman, National Institutes of Health, Bethesda, MD; Zev A. Wainberg, University of California Los Angeles, Los Angeles, CA; Jae Yong Cho, Yonsei University College of Medicine Gangnam Severance Hospital; Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht Institute for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Zielinski","sequence":"additional","affiliation":[{"name":"Vivek Subbiah and Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert J. Kreitman, National Institutes of Health, Bethesda, MD; Zev A. Wainberg, University of California Los Angeles, Los Angeles, CA; Jae Yong Cho, Yonsei University College of Medicine Gangnam Severance Hospital; Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht Institute for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Cabanillas","sequence":"additional","affiliation":[{"name":"Vivek Subbiah and Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert J. Kreitman, National Institutes of Health, Bethesda, MD; Zev A. Wainberg, University of California Los Angeles, Los Angeles, CA; Jae Yong Cho, Yonsei University College of Medicine Gangnam Severance Hospital; Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht Institute for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gladys","family":"Urbanowitz","sequence":"additional","affiliation":[{"name":"Vivek Subbiah and Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert J. Kreitman, National Institutes of Health, Bethesda, MD; Zev A. Wainberg, University of California Los Angeles, Los Angeles, CA; Jae Yong Cho, Yonsei University College of Medicine Gangnam Severance Hospital; Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht Institute for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijoyesh","family":"Mookerjee","sequence":"additional","affiliation":[{"name":"Vivek Subbiah and Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert J. Kreitman, National Institutes of Health, Bethesda, MD; Zev A. Wainberg, University of California Los Angeles, Los Angeles, CA; Jae Yong Cho, Yonsei University College of Medicine Gangnam Severance Hospital; Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht Institute for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dazhe","family":"Wang","sequence":"additional","affiliation":[{"name":"Vivek Subbiah and Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert J. Kreitman, National Institutes of Health, Bethesda, MD; Zev A. Wainberg, University of California Los Angeles, Los Angeles, CA; Jae Yong Cho, Yonsei University College of Medicine Gangnam Severance Hospital; Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht Institute for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Rangwala","sequence":"additional","affiliation":[{"name":"Vivek Subbiah and Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert J. Kreitman, National Institutes of Health, Bethesda, MD; Zev A. Wainberg, University of California Los Angeles, Los Angeles, CA; Jae Yong Cho, Yonsei University College of Medicine Gangnam Severance Hospital; Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht Institute for..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[{"name":"Vivek Subbiah and Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert J. Kreitman, National Institutes of Health, Bethesda, MD; Zev A. Wainberg, University of California Los Angeles, Los Angeles, CA; Jae Yong Cho, Yonsei University College of Medicine Gangnam Severance Hospital; Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht Institute for..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<564::AID-CNCR20>3.0.CO;2-0"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20936"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0395"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0147"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2482-13-S2-S44"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddu749"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85271"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0076"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1067\/msy.2001.118266"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1404357111"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1210093"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406037"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx176"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30146-2"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3541"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70057-2"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0456"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46382"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-4463"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1015557108"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502309"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-1518"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.08.022"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0297"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0631"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9023"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2017.73.6785","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T06:29:19Z","timestamp":1653805759000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2017.73.6785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1,1]]}},"alternative-id":["10.1200\/JCO.2017.73.6785"],"URL":"https:\/\/doi.org\/10.1200\/jco.2017.73.6785","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732036348.793556563","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,1]]},"assertion":[{"value":"2017-10-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}